Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with South Korean firm Myung In Pharm. Under the agreement, Myung In Pharm has been granted commercialization rights to Luye’s rivastigmine twice-weekly transdermal patch (LY03013) in South Korea. The drug is indicated for the treatment of symptoms associated with mild to moderate Alzheimer’s disease (AD).
Luye’s twice-weekly patch offers a significant advantage over commercially available single-day transdermal patches, as it reduces the frequency of administration and enhances patient adherence. When compared to oral formulations, the patch also helps to mitigate gastrointestinal adverse reactions such as nausea and vomiting through transdermal delivery, leading to more stable blood drug concentrations in steady-state conditions. This makes the product particularly convenient for patients who have difficulty swallowing oral medications.
LY03013, a modified version of rivastigmine developed on Luye’s proprietary transdermal patch platform, has already received marketing authorization in several European countries. Luye has successfully secured partnerships with local firms for the product’s commercialization in various markets, including European countries, Japan, China, Mexico, and Thailand.
This licensing agreement with Myung In Pharm further expands the global reach of Luye’s innovative transdermal patch, offering a more patient-friendly alternative for the management of Alzheimer’s disease symptoms.- Flcube.com
